Overview

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The objective of this pivotal study is to evaluate the relative bioavailability of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in healthy volunteers without charcoal block.
Phase:
Phase 1
Details
Lead Sponsor:
Intech Biopharm Ltd.
Treatments:
Charcoal
Fluticasone
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Salmeterol Xinafoate
Xhance